- Ionis Pharmaceuticals (NASDAQ:IONS) promotes Eugene Schneider to EVP and chief clinical development officer.
- Dr. Schneider joined Ionis in 2013 and has played a key role in more than 20 clinical trials conducted in the U.S. and globally. In this new role, Dr. Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises.
- Before joining Ionis, Dr. Schneider was senior medical director, clinical research and development at Synageva BioPharma, where he developed a novel enzyme replacement therapy for Lysosomal Acid Lipase Deficiency from its first-in-man study to registration. Prior to Synageva, he was senior medical director, medical and scientific affairs at Biovail Technologies.
- Stock up 0.71% AH.
- Previously (Dec. 18, 2020): Ionis rises as the founder retires
Ionis Pharma names Eugene Schneider as its clinical development chief
Recommended For You
About IONS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IONS | - | - |
Ionis Pharmaceuticals, Inc. |